These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29266038)

  • 1. Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation.
    Uygunoglu U; Tutuncu M; Altintas A; Saip S; Siva A
    Neurologist; 2018 Jan; 23(1):12-16. PubMed ID: 29266038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
    Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
    Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Sclerosis Relapses Following Cessation of Fingolimod.
    Malpas CB; Roos I; Sharmin S; Buzzard K; Skibina O; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T;
    Clin Drug Investig; 2022 Apr; 42(4):355-364. PubMed ID: 35303292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
    Callens A; Leblanc S; Le Page E; Edan G; Jourdain A; Coustans M; Wiertlewski S; Laplaud D; Videt D; Lallement F; Leray E; Michel L
    Mult Scler Relat Disord; 2022 Oct; 66():104066. PubMed ID: 35908450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 8. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
    Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
    Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients.
    Ribeiro de Barros AH; Fiadeiro Sequeira JP; Lopes de Sousa AS; Cheganças Capela CM; Gomes Pedrosa RM; Dos Santos Manita MA
    Clin Neuropharmacol; 2018; 41(4):129-135. PubMed ID: 29927805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
    Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
    CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
    Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
    Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Hemat S; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould AM
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37217309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
    Zivadinov R; Medin J; Khan N; Korn JR; Chitnis T; Naismith RT; Alvarez E; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2019 Jan; 27():65-73. PubMed ID: 30342416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
    Ueda N; Saida K
    BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What happens after fingolimod discontinuation? A multicentre real-life experience.
    Landi D; Signori A; Cellerino M; Fenu G; Nicoletti CG; Ponzano M; Mancuso E; Fronza M; Ricchiuto ME; Boffa G; Inglese M; Marfia GA; Cocco E; Frau J
    J Neurol; 2022 Feb; 269(2):796-804. PubMed ID: 34136943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
    Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
    Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
    Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
    J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.